Comparing the Efficacy Ofbromfenac 0.09% and Nepafenac 0.1% Post Cataract Surgery: A Prospective Evaluation

Duong, Hon-Vu Q.; Westfield, Kenneth C.; Singleton, Isaac C.

doi:10.4172/2155-9570.1000177

Cited by 6 publications

(8 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Overall, published data with bromfenac 0.07% and 0.09% strongly suggest the efficacy for the prevention of CME or markers of macular changes and for the treatment of CME. Few studies of bromfenac for the prevention or treatment of CME directly reported safety outcomes, although the studies that did so found bromfenac to be safe and well tolerated, with minimal risk of increased IOP 57,58,61,65,66,68,69,77. In the placebo-controlled studies cited in this review,55,56 the incidence of AEs was significantly lower in bromfenac-treated groups compared with placebo groups.…”

Section: Resultsmentioning

confidence: 90%

“…Duong et al68 prospectively compared bromfenac 0.09% and nepafenac 0.1% in a randomized, masked study in patients undergoing cataract surgery. Both treatments were administered for 3 days prior to surgery and continued through 7 days postsurgery.…”

Section: Bromfenac For the Prevention Of Cme Postcataract Surgerymentioning

confidence: 99%

“…The findings on the efficacy of bromfenac for the prevention of CME in cataract surgery patients with diabetes are derived from two studies conducted specifically in this patient population69,70 and from three subanalyses of data from studies that included patients with diabetes 60,65,68…”

Section: Bromfenac For the Prevention Of Cme Postcataract Surgerymentioning

confidence: 99%

“…A subanalysis of patients with diabetes from the study of Duong et al68 compared 29 eyes treated with bromfenac 0.09% and 30 eyes treated with nepafenac 0.1%, both in combination with postoperative prednisolone acetate. None of the patients with diabetes in either treatment group developed clinical CME, and two patients in each group developed CME by OCT within 1 month postsurgery.…”

Section: Bromfenac For the Prevention Of Cme Postcataract Surgerymentioning

confidence: 99%

“…No significant differences in the incidence of CME were observed when bromfenac monotherapy was compared to steroid monotherapy57,60 or bromfenac used in conjunction with a steroid 61. Studies comparing bromfenac with other NSAIDs observed no significant differences in the CME rates between bromfenac and nepafenac when given alone or in combination with corticosteroids66,68 or between bromfenac and ketorolac when given in combination with a corticosteroid 65…”

Section: Bromfenac For the Prevention Of Cme Postcataract Surgerymentioning

confidence: 99%

See 4 more Smart Citations

Topical bromfenac for prevention and treatment of cystoid macular edema following cataract surgery: a review

Sheppard¹

2016

OPTH

View full text Add to dashboard Cite

Topical nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids, alone or in combination, have historically been used off label in the US to prevent and treat postoperative cystoid macular edema (CME). This literature review presents available data on the use of bromfenac 0.07% or 0.09% to prevent and treat CME following cataract surgery. Bromfenac is an NSAID approved to treat postoperative inflammation and reduce ocular pain following cataract surgery. Few cases of clinical CME were observed with bromfenac use in a total of 19 reviewed studies. There were no significant differences in CME incidence between bromfenac and corticosteroid-treated patients or between bromfenac- and bromfenac plus corticosteroid-treated patients. Bromfenac demonstrated comparable efficacy to other NSAIDs in preventing CME. Compared with corticosteroids, bromfenac alone or plus a corticosteroid showed similar or better efficacy in minimizing changes in retinal thickness and macular volume. In diabetic cataract surgery patients, bromfenac was comparable or superior to corticosteroids for minimizing changes in retinal thickness; also, combination therapy with bromfenac and corticosteroids may be associated with smaller changes in foveal thickness, macular thickness, and macular volume versus monotherapy with either treatment alone in this patient population. In two randomized, double-masked, placebo-controlled clinical trials with bromfenac 0.07%, CME was reported as an adverse event in 0.5% and 1.5% of patients receiving bromfenac and placebo, respectively. In an analysis of four placebo-controlled trials with bromfenac 0.09%, macular edema was reported in 0.7% and 1.4% of patients receiving bromfenac and placebo, respectively. When evaluated as treatment for acute or chronic CME, bromfenac was associated with improvement in visual acuity and reduction in retinal thickness, but few studies are available. Overall, published data suggest that bromfenac is safe and effective when used to prevent or treat CME. Large-scale placebo-controlled trials and greater standardization of CME measures are needed to establish optimal bromfenac regimens for the prophylaxis and treatment of CME following cataract surgery.

show abstract